- Home
- INTG vs BLRX Comparison
INTG vs BLRX Comparison
Compare INTG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTG
- BLRX
- Stock Information
- Founded
- INTG 1965
- BLRX 2003
- Country
- INTG United States
- BLRX Israel
- Employees
- INTG N/A
- BLRX N/A
- Industry
- INTG Building operators
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- INTG Real Estate
- BLRX Health Care
- Exchange
- INTG Nasdaq
- BLRX Nasdaq
- Market Cap
- INTG 30.8M
- BLRX 36.0M
- IPO Year
- INTG N/A
- BLRX 2011
- Fundamental
- Price
- INTG $14.34
- BLRX $0.46
- Analyst Decision
- INTG
- BLRX Strong Buy
- Analyst Count
- INTG 0
- BLRX 2
- Target Price
- INTG N/A
- BLRX $11.50
- AVG Volume (30 Days)
- INTG 6.3K
- BLRX 410.3K
- Earning Date
- INTG 11-13-2024
- BLRX 11-18-2024
- Dividend Yield
- INTG N/A
- BLRX N/A
- EPS Growth
- INTG N/A
- BLRX N/A
- EPS
- INTG N/A
- BLRX N/A
- Revenue
- INTG $59,536,000.00
- BLRX $17,048,000.00
- Revenue This Year
- INTG N/A
- BLRX N/A
- Revenue Next Year
- INTG N/A
- BLRX N/A
- P/E Ratio
- INTG N/A
- BLRX N/A
- Revenue Growth
- INTG 0.93
- BLRX N/A
- 52 Week Low
- INTG $13.65
- BLRX $0.39
- 52 Week High
- INTG $28.85
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- INTG 44.26
- BLRX 48.89
- Support Level
- INTG $14.18
- BLRX $0.40
- Resistance Level
- INTG $14.41
- BLRX $0.46
- Average True Range (ATR)
- INTG 0.47
- BLRX 0.03
- MACD
- INTG 0.08
- BLRX 0.01
- Stochastic Oscillator
- INTG 49.23
- BLRX 72.96
About INTG Intergroup Corporation (The)
The Intergroup Corp is an us-based company operating in the real estate sector. It is formed to buy, develop, operate, rehabilitate and dispose of real property of various types and descriptions, and to engage in other related business and investment activities. The company operates through three segments namely Hotel Operations, Real Estate Operations, and Investment Transactions. The Hotel Operations segment which generates the majority of the revenue covers the operation of the Hilton hotel and garage. The Real Estate Operations segment consists of the operation of multifamily rental properties whereas the Investment Transactions segment includes an investment of cash in marketable securities and other investments.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.